# EDGAR Filing Document

**Accession Number:** 0001814140
**File Stem:** 0000950170-23-008812
**Filing Date:** 2023-3
**Character Count:** 2863
**Document Hash:** 5c564a528e30a37b673c77fc2a3e2598
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-008812.hdr.sgml**: 20230418

**ACCESSION NUMBER**: 0000950170-23-008812

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apexigen, Inc.
- **CENTRAL INDEX KEY:** 0001814140
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 851260244
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 900 INDUSTRIAL ROAD, SUITE C
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070
- **BUSINESS PHONE:** 650.931.6236

**MAIL ADDRESS:**
- **STREET 1:** 900 INDUSTRIAL ROAD, SUITE C
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brookline Capital Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200603

March 20, 2023

**VIA EDGAR** 

U.S. Securities and Exchange Commission

Division of Corporation Finance,

100 F Street, N.E.

Washington, D.C. 20549-3628

---

| | |
|:---|:---|
| Attention: | Josh Gorsky and Joe McCann |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Re:** | **Apexigen, Inc.<br>Registration Statement on Form S-1**<br>**File No. 333-269912** |

---

**Acceleration Request**

**Requested Date: March 21, 2023**

**Requested Time: 4:05 p.m. Eastern Time,**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**or as soon thereafter as practicable**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Apexigen, Inc. (the "**Company**") hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-269912) (the "**Registration Statement**") be declared effective at the "Requested Date" and "Requested Time" set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.

Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Lance Brady at (650) 565-3836.

Please direct any questions or comments regarding this acceleration request to Lance Brady at (650) 565-3836.

[Signature page follows]

------

Sincerely,

Apexigen, Inc.

<u>/s/ Xiaodong Yang</u> 

Xiaodong Yang, M.D., Ph.D.

Chief Executive Officer

cc: Francis Sarena, Apexigen, Inc.Michael E. Coke, Wilson Sonsini Goodrich & Rosati, Professional CorporationLance Brady, Wilson Sonsini Goodrich & Rosati, Professional Corporation

------